Foghorn Therapeutics (FHTX) Change in Accured Expenses (2019 - 2026)

Foghorn Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 85.21% year-over-year to -$4.5 million; the TTM figure through Mar 2026 stood at $153000.0 (up 193.87% YoY), while the FY2025 annual figure was $2.2 million, up 490.78% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.5 million, down from $1.4 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.0 million in Q3 2024, with the low at -$4.5 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $332000.0 (2023), against an average of -$186705.9.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses plunged 829.22% in 2024, then soared 764.14% in 2025.
• Foghorn Therapeutics' Change in Accured Expenses stood at $894000.0 in 2022, then sank by 62.86% to $332000.0 in 2023, then slumped by 829.22% to -$2.4 million in 2024, then surged by 159.27% to $1.4 million in 2025, then sank by 410.66% to -$4.5 million in 2026.
• Business Quant data shows FHTX's Change in Accured Expenses at -$4.5 million in Q1 2026, $1.4 million in Q4 2025, and $1.2 million in Q3 2025.